What happened: British company BioOrbit launched a device to the International Space Station to grow ultra-pure protein crystals for cancer drugs. The compact unit, Box-E, aims to improve drug quality through space-based crystallisation.
Why it matters:
- Could lead to more effective, self-injected cancer treatments benefiting millions.
- Represents innovation in pharmaceutical manufacturing by using microgravity environments.
MNN Take: BioOrbit’s space-based approach seeks to enhance drug purity, potentially improving treatment options. This project highlights growing interest in utilising space conditions for medical advances.
Sources: Guardian UK